Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    Lower Childhood IQ Associated With Higher Risk of Adult Mental Disorders - (DGNews)
    Eye Divergence in Children Triples Risk of Mental Illness - (DGNews)
    Ginkgo Evaluation of Memory Study Fails to Show Benefit in Preventing Dementia in the Elderly - (DGNews)
    Psychological Interventions Associated With Breast Cancer Survival - (DGNews)
    Safety and Tolerability of Quetiapine in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia: Presented at AACAP - (DGDispatch)

    News archive

     Recent webcasts/CME - Psychiatry Other

    Webcasts/CME archive

     Recent cases - Psychiatry Other
      Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
      Treating Bipolar Disorder in Patients with Renal Failure Having Haemodialysis: Two Case Reports
      Lithium Intoxication Related Multiple Temporary ECG Changes : A Case Report
      Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
      Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report

      Cases archive
        




      my personal edition > psychiatry other > news
      divider

        E-Mail this DGNews to a colleague

      DGNews


      Alliant Pharmaceuticals Announces Return of Chewable Tablets for ADHD

      Treatment includes chewable tablets and oral solution

      ALPHARETTA, G.A. -- June 6, 2006 -- Alliant Pharmaceuticals, Inc., a leading pediatric specialty pharmaceutical company, today announced the re-introduction of Methylin Chewable Tablets (methylphenidate HCL).

      The product is the first, and only, chewable tablet for use in the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in children.

      Methylin is considered the gold standard for treating children for ADHD. ADHD is a disorder of the brain in which the individual repeatedly exhibits inappropriate impulsivity and/or inattention. According to the Attention Deficit Disorder Association, an estimated 5-10 percent of school age children, and an estimated 3-6 percent of adults suffer from ADHD.

      Studies show that more than 50% of children ages 12 and under have difficulty swallowing tablets and capsules. "We are excited to have both Methylin Chewable Tablets and Methylin Oral Solution available for physicians to help improve patient compliance," stated Mark Pugh, President and CEO of Alliant. "Each of these medications was designed specifically to help improve efficacy in treatment."

      Alliant voluntarily removed the Methylin Chewable Tablets from the market in February 2005 after its manufacturer, Mallinckrodt, discovered a blending issue in the manufacturing process that could affect dosage potency. Pugh adds that the manufacturing issue was resolved and no further issues exist.

      Methylin Chewable Tablets are available in a 2.5mg, 5mg and 10mg dose. The Methylin Oral Solution is available in a 5mg / 5mL and 10mg / 5mL dose.


      SOURCE: Alliant Pharmaceuticals, Inc.



      E-Mail this DGNews to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send